Plexin-B1 Mutation Drives Metastasis in Prostate Cancer Mouse Models.


Journal

Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676

Informations de publication

Date de publication:
03 2023
Historique:
received: 22 11 2022
revised: 10 01 2023
accepted: 10 02 2023
entrez: 20 3 2023
pubmed: 21 3 2023
medline: 21 3 2023
Statut: epublish

Résumé

Metastatic prostate cancer is essentially incurable and is a leading cause of cancer-related morbidity and mortality in men, yet the underlying molecular mechanisms are poorly understood. Plexins are transmembrane receptors for semaphorins with divergent roles in many forms of cancer. We show here that prostate epithelial cell-specific expression of a mutant form of Plexin-B1 ( Few therapeutic targets have been identified specifically for preventing locally invasive/oligometastatic prostate cancer from becoming more widely disseminated. Our findings suggest Plexin-B1 signaling, particularly from the clinically relevant

Identifiants

pubmed: 36936664
doi: 10.1158/2767-9764.CRC-22-0480
pii: CRC-22-0480
pmc: PMC10019359
doi:

Substances chimiques

Proto-Oncogene Proteins p21(ras) EC 3.6.5.2
Receptors, Cell Surface 0
Antineoplastic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

444-458

Informations de copyright

© 2023 The Authors; Published by the American Association for Cancer Research.

Références

Immunity. 2001 May;14(5):523-34
pubmed: 11371355
Nature. 2012 Jul 12;487(7406):239-43
pubmed: 22722839
Oncogene. 2016 Feb 25;35(8):1066-72
pubmed: 25982277
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Mech Dev. 2001 Mar;101(1-2):61-9
pubmed: 11231059
J Biol Chem. 2009 Dec 18;284(51):35962-72
pubmed: 19843518
J Clin Invest. 2012 Apr;122(4):1296-305
pubmed: 22378040
Urol Oncol. 2018 Aug;36(8):349-360
pubmed: 29887240
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
Sci Signal. 2012 Jan 17;5(207):ra6
pubmed: 22253263
Prostate. 2013 Sep;73(12):1326-35
pubmed: 23775445
Am J Pathol. 2011 Jul;179(1):422-35
pubmed: 21703421
Nat Rev Drug Discov. 2014 Aug;13(8):603-21
pubmed: 25082288
J Biol Chem. 2008 Jan 25;283(4):1893-901
pubmed: 18025083
Nat Commun. 2022 May 3;13(1):2400
pubmed: 35504881
Cells. 2019 Dec 18;9(1):
pubmed: 31861264
Cancer Cell. 2010 Jul 13;18(1):11-22
pubmed: 20579941
J Biol Chem. 2007 Dec 21;282(51):37215-24
pubmed: 17916560
Nat Cell Biol. 2002 Sep;4(9):720-4
pubmed: 12198496
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9017-22
pubmed: 16754882
Clin Cancer Res. 2007 Feb 15;13(4):1115-22
pubmed: 17317819
Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12457-62
pubmed: 11035813
Cancer Res. 2012 Apr 1;72(7):1878-89
pubmed: 22350410
FEBS Lett. 2008 Jun 18;582(14):2093-101
pubmed: 18460342
PLoS One. 2013;8(1):e53501
pubmed: 23308238
Neuron. 2002 Jul 3;35(1):51-63
pubmed: 12123608
PLoS Biol. 2010 Jun 29;8(6):e1000412
pubmed: 20613859
Sci Rep. 2018 Jun 15;8(1):9227
pubmed: 29907753
J Cell Sci. 2016 Nov 1;129(21):4046-4056
pubmed: 27656111
Cancer Biol Med. 2017 Feb;14(1):90-99
pubmed: 28443208
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436
pubmed: 31061129
Investig Clin Urol. 2017 Sep;58(5):307-316
pubmed: 28868501
PLoS One. 2017 Oct 17;12(10):e0185899
pubmed: 29040270
Trends Cell Biol. 2000 Sep;10(9):377-83
pubmed: 10932095
J Cell Biol. 2004 Jun 21;165(6):869-80
pubmed: 15210733
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Nat Commun. 2021 Feb 26;12(1):1308
pubmed: 33637728
Nat Cell Biol. 2015 Jan;17(1):81-94
pubmed: 25531777
J Pathol. 2017 Dec;243(4):442-456
pubmed: 29134654
Neuron. 2001 Oct 11;32(1):39-51
pubmed: 11604137
Nat Rev Mol Cell Biol. 2005 Oct;6(10):789-800
pubmed: 16314868
Cancer Cell. 2003 Aug;4(2):111-20
pubmed: 12957286
Genes Dev. 2000 Apr 15;14(8):994-1004
pubmed: 10783170
J Cell Sci. 2012 Aug 1;125(Pt 15):3557-67
pubmed: 22505611
Mol Cancer. 2012 Mar 09;11:11
pubmed: 22404908
Nat Med. 2016 Mar;22(3):298-305
pubmed: 26855148
EMBO Rep. 2009 Jun;10(6):614-21
pubmed: 19444311
Cancer Res. 2009 Jun 15;69(12):4962-8
pubmed: 19470770
J Biol Chem. 2003 Jul 11;278(28):25671-7
pubmed: 12730235
Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):19040-5
pubmed: 18024597
Nat Cell Biol. 2005 Mar;7(3):255-61
pubmed: 15723050
Oncotarget. 2017 Sep 19;8(50):88211-88231
pubmed: 29152153
J Exp Med. 2008 Jul 7;205(7):1673-85
pubmed: 18559453
Science. 2004 Aug 6;305(5685):862-5
pubmed: 15297673
J Invest Dermatol. 2010 Jun;130(6):1636-45
pubmed: 20164843
Sci Rep. 2017 Sep 13;7(1):11501
pubmed: 28904399
J Biol Chem. 2010 Sep 3;285(36):28200-9
pubmed: 20610402
Blood. 2005 Jun 1;105(11):4321-9
pubmed: 15632204
BMC Cancer. 2010 Nov 08;10:611
pubmed: 21059203
J Neurosci. 2007 Jun 6;27(23):6333-47
pubmed: 17554007

Auteurs

Boris Shorning (B)

European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Cardiff, United Kingdom.

Neil Trent (N)

European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Cardiff, United Kingdom.

David F Griffiths (DF)

Department of Cellular Pathology, University Hospital of Wales, Cardiff, United Kingdom.

Thomas Worzfeld (T)

Institute of Pharmacology, University of Marburg, Marburg, Germany.
Department of Pharmacology, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany.

Stefan Offermanns (S)

Department of Pharmacology, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany.

Matthew J Smalley (MJ)

European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Cardiff, United Kingdom.

Magali Williamson (M)

School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH